evipedia.ai
← Back

Cortexin for Health & Longevity

Evidence Review created on 08/31/2026 using AI4L / Opus 5

Also known as: Kortexin, Korteksin, Cortexinum, Bovine Cerebral Cortex Polypeptides

Motivation

Cortexin is an injected medicine made from a purified extract of cattle brain cortex — a mixture of small protein fragments, free amino acids and trace minerals. It is sold in Russia and neighbouring countries as a brain-protecting treatment and reaches people elsewhere through import channels. Interest among longevity-minded adults comes from the claim that a short course of injections can sharpen thinking and lift fatigue that has resisted other approaches.

The preparation was developed inside the Soviet military medical system in the 1980s and licensed as a civilian medicine at the end of the 1990s. Since then it has been given to very large numbers of patients across that region, mostly after strokes and in long-standing circulatory brain disease. Almost all of the published human experience comes from that one region, and much of it was funded by the company that makes the product.

This review examines what the available human and laboratory evidence shows about Cortexin: what it appears to do, how large the reported changes are, what harms have been recorded, how it is dosed and cycled, and how much weight the underlying research can carry.

Benefits - Risks - Protocol - Conclusion

This section collects high-level, directly relevant material on Cortexin from expert commentary and qualifying academic sources.

No priority platform reaches the topic at all. Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine and Lifespan.io all return no results for the preparation on their own site searches, and their peptide coverage addresses unrelated compounds. Only four qualifying sources exist, so four rather than five are listed; beyond them the remaining English-language material is vendor copy or database entries, and the list has not been padded with it.

Grokipedia

Cortexin

This is the site’s dedicated page for the preparation, and it gathers the bovine-cortex composition, the mechanism its manufacturer claims, the registered indications across post-Soviet markets and the dosing schedules in one place.

Examine

No Examine article exists for Cortexin. Examine.com covers dietary supplements and does not typically cover prescription medications, and Cortexin is a prescription-only injectable medicine in every market where it is registered.

ConsumerLab

No ConsumerLab article or test report exists for Cortexin. ConsumerLab tests retail dietary supplements sold in the United States and does not typically cover prescription medications; Cortexin is a prescription injectable not marketed there.

Systematic Reviews

This section lists the systematic review and meta-analysis literature that examines Cortexin directly.

Only one systematic review covers this intervention, and it addresses both sides of the trade-off in a single document: the claimed cognitive benefit and the serious-adverse-event outcome. No systematic review addresses the principal risk of the intervention — repeated exposure to an injected animal-brain-derived protein — as a question in its own right, so that side of the trade-off is unrepresented in the review literature.

Mechanism of Action

Cortexin is not a single molecule. It is a freeze-dried mixture of water-soluble polypeptide fractions of roughly 1,000–10,000 daltons, free amino acids, vitamins and trace elements extracted from the cerebral cortex of cattle, so its proposed actions are plural rather than single-target (Gomazkov, 2015).

In receptor-binding assays it bound AMPA receptors (the fast-acting excitatory glutamate receptor) at 80.1%, kainate receptors at 73.5%, mGluR1 (a slower, tone-setting glutamate receptor) at 49.0%, GABA-A1 (the brain’s main inhibitory receptor) at 44.0% and mGluR5 at 39.7% — a profile read as damping glutamate-driven excitotoxicity (the nerve-cell death caused by overexcitation), while supporting inhibitory tone. Radiolabeled material crossed the blood-brain barrier in mice at 6–8% of whole-blood concentration (Kurkin et al., 2021). In brain tissue it selectively inhibits caspase-8, an enzyme that starts one route of programmed cell death, while barely touching caspases-1, -3 and -9 (Yakovlev et al., 2017), and its peptides bind the neuron proteins β5-tubulin, creatine kinase B (an energy-buffering enzyme) and 14-3-3 α/β (Gulyaeva, 2018).

Pharmacologically it behaves as a peptide, not a small molecule: no cytochrome P450 (the liver’s main drug-metabolizing enzyme family) involvement, breakdown by peptidases present throughout the body, and no published elimination half-life; distribution studies show brain uptake tracking blood level and no tissue depot (Kurkin et al., 2025).

The competing explanation is that peptides of this size are hydrolyzed before reaching the brain intact, so any effect reflects non-specific amino-acid and trace-element delivery, or expectation around a daily injection.

Historical Context & Evolution

Cortexin was created in 1986 at the Military Medical Academy in Leningrad, inside a Soviet program searching for “peptide bioregulators” — tissue-specific extracts intended to restore function in the organ they came from. The original brief was military: acute brain trauma, oxygen-deprivation injury and the neurological aftermath of blast and radiation exposure. The same program produced pineal and thymic extracts and, later, the short synthetic peptides Epithalon, Cortagen and Pinealon.

Civilian registration in Russia followed at the end of the 1990s, accompanied by a controlled trial in 76 patients with early circulatory encephalopathy (a slow decline in brain function from reduced blood flow), in which Cortexin raised rehabilitation efficiency by 22.7% over standard therapy and improved attention, memory and thinking (Khavinson et al., 1999). A review of the accumulated Soviet and Russian work concluded that the preparation acted chiefly on memory and attention across several patient groups (Tsyganov & Bogoslovskii, 2004).

Use then spread well beyond the original brief — into pediatric neurology (Zykov et al., 2018), epilepsy, alcohol-related brain injury and, after 2020, post-viral cognitive complaints. Health-optimization interest followed the same path as other Soviet-era neuropeptides: from hospital indication to grey-market self-experimentation.

Opinion has not converged. Regional neurology treats the preparation as an established add-on therapy; the one independent appraisal found a single eligible trial and rated certainty low to very low (Alsulaimani & Quinn, 2021). What changed was not a refutation but outside assessment against standards the original literature was never built to meet.

Expected Benefits

High 🟩 🟩 🟩

Functional Recovery After Acute Ischemic Stroke

Started within days of an ischemic stroke (a stroke caused by a blocked artery), Cortexin is added to standard care to speed the return of movement and independence. Two randomized, double-blind, placebo-controlled multicenter trials, of 272 and 490 patients, measured disability on the modified Rankin scale (a 0–6 disability rating) and deficit on the National Institutes of Health Stroke Scale, both validated. Both ran in Russia with the manufacturer, Geropharm, involved, and neither has been replicated abroad (Aliferova et al., 2014; Fedin et al., 2025).

Magnitude: In the 490-patient trial, 86.5–93.6% of patients reached a modified Rankin score of 0–2 by day 90 and stroke-scale scores fell 3.7–3.9 points; because both arms received active drug by different routes, the increment attributable to Cortexin itself is not quantified.

Medium 🟩 🟩

Cognitive Improvement in Chronic Cerebrovascular Disease

Repeated 10-day courses raise scores on standard cognitive screens in people with long-standing reduced brain blood flow. A 189-patient randomized controlled trial found dose-dependent improvement in neurological symptoms, with cognitive testing improving at both doses; observational programs of 495 and 801 patients, and a 979-patient uncontrolled program in post-viral illness, reported gains on the Mini-Mental State Examination (a 30-point cognitive screen) (Fedin et al., 2018; Fedin, 2018; Mashin et al., 2023; Putilina et al., 2022). Only that trial was controlled; the independent review rated certainty low to very low.

Magnitude: Reported gains run 1–4 points on 30-point cognitive screens after one or two 10-day courses, without a consistent difference between 10 mg and 20 mg daily; the independent review judged the class-wide effect smaller than a clinically meaningful difference (Alsulaimani & Quinn, 2021).

Reduction of Asthenia and Fatigue

Asthenia (persistent weakness and exhaustion out of proportion to exertion) is the symptom the preparation is most often given for outside stroke care. The 189-patient randomized trial measured it on the Multidimensional Fatigue Inventory and found a dose-dependent reduction, larger at 20 mg than 10 mg and clearer after a repeat course (Fedin et al., 2018). A 979-patient observational program in post-viral illness reported the same direction on the same instrument but had no control arm (Putilina et al., 2022).

Magnitude: The effect is dose-dependent, greater at 20 mg than at 10 mg daily and clearest after a second 10-day course; the published reports state direction and dose-dependence only and give no effect-size figure for the fatigue scales.

Improved Sleep Quality

The same randomized trial tracked sleep on the Spiegel sleep questionnaire and found dose-dependent improvement alongside the fatigue and neurological changes, consistent with the preparation’s reported binding to inhibitory receptors. Sleep was a secondary endpoint in a trial not designed around it, the population had established cerebrovascular disease, and no sleep-laboratory measurement was taken, so the finding rests on self-report in a single trial (Fedin et al., 2018). Insomnia also appears on the product’s rare-adverse-event list, making direction sensitive to dose timing.

Magnitude: Sleep-questionnaire scores improved in a dose-dependent manner at 10 and 20 mg daily, most clearly after a repeat course six months later; the trial report gives direction and dose-dependence without an effect-size figure.

Relief of Diabetic Nerve Symptoms

A 110-patient randomized multicenter trial added ten 10 mg injections to standard vitamin and glycine therapy in type 2 diabetes with painless nerve damage, following patients for 90 days. Nerve-symptom scores and central sensitization scores (a measure of amplified pain signaling) improved more than in controls, and glycated hemoglobin fell further — an unexpected metabolic finding not yet replicated (DIACORT, 2026). Cell-culture work supports plausibility in high-glucose conditions (Yazar & Ayar, 2023).

Magnitude: Nerve-symptom scores fell 2.8-fold versus 1.3-fold in controls, central sensitization scores 1.8-fold versus 1.2-fold, and glycated hemoglobin reached 7.3% versus 7.8%, all at p<0.001 (a difference this large would arise by chance less than once in a thousand times) over 90 days.

Low 🟩

Reduction of Anxiety and Depressive Symptoms ⚠️ Conflicted

A 98-patient add-on trial (Schastnyy, 2026) and a 110-patient diabetes trial (DIACORT, 2026) both found mood scores falling markedly, while the 189-patient cerebrovascular trial called the same effects insignificant (Fedin et al., 2018). Net reading: the effect appears where a mood disorder is being treated, not in general use.

Magnitude: Anxiety scores fell 1.6-fold and depression scores 1.7-fold over 90 days in the 110-patient diabetes trial against minimal change in controls; the cerebrovascular trial found no significant change after a single course.

Work Capacity in Adults Without Neurological Disease

Two small controlled trials tested Cortexin outside neurological disease. A two-week course raised professional working capacity in older university teachers, most with added breathing exercises (Lysenko et al., 2020). In healthy volunteers aged 20-24 it improved efficiency only under simulated high-altitude low oxygen (Shabanov et al., 2007).

Magnitude: Gains peaked at the end of the two-week course and faded over roughly two months in the teachers; in the climate-chamber trial the effect held only under low-oxygen conditions, and neither report gives an effect-size figure.

Recovery After Traumatic Brain Injury

Cortexin is licensed for the consequences of head injury, but the controlled human data are pediatric. Seventy-four children aged 6-13 with moderate brain contusion recovered focal neurological signs and cognitive function faster than controls, with normalized brain electrical activity (Skripnik et al., 2020). No adult trial exists.

Magnitude: Subjective and focal neurological symptoms regressed further than in controls by day 30 and brain electrical activity normalized; the report gives direction and significance only, with no effect-size figure.

Seizure Frequency in Epilepsy ⚠️ Conflicted

Cortexin has been reported both to reduce and to worsen seizures. Sixty-four adults on three courses had significantly fewer seizures (Belskaya & Ponomareva, 2014); 86 children showed no aggravation in 95%, implying worsening in 5% (Kalmykova et al., 2021). Net reading: neither series was controlled, so direction is unpredictable.

Magnitude: Seizure frequency fell significantly across three 10-day courses in the 64-adult series while about 5% of 86 children worsened; neither report gives a rate ratio or an absolute change.

Recovery of Speech After Stroke

Seventy-one patients with post-stroke aphasia (loss of language ability) received 10 mg twice daily plus app-based speech rehabilitation, or rehabilitation alone. Speech, writing and reading scores improved more in the combined group, but allocation was by consent, not randomization (Kuznetsova et al., 2024).

Magnitude: Speech scores rose from 141.8 to 214.3 of a possible 262, writing from 20.5 to 31.5 of 44 and reading from 14.5 to 24.4 of 29 between admission and discharge in the combined group.

Speculative 🟨

Restoration of Antioxidant Balance

Human trials measured only free thiol groups and antioxidant enzyme activity (Fedin et al., 2018); rat work measured related oxidative-stress markers (Kurkin et al., 2021). These are unvalidated biomarkers with no demonstrated outcome link.

Geroprotective Effect on the Aging Brain

Claims of slowed brain aging rest on rodent work: developmental-delay models in which treated animals kept more undamaged cortical neurons. No human study has measured any aging endpoint (Kurkin et al., 2025).

Protection Against Drug-Induced Neural and Cochlear Damage

Rats given cisplatin retained more hearing when co-treated (Eroğlu et al., 2018), and cultured sensory neurons survived high glucose better (Yazar & Ayar, 2023). Both lack any human counterpart.

Benefit-Modifying Factors

  • Baseline cognitive score: Reported gains are largest where the starting score is lowest. Trials enrolling people with established cognitive impairment show 1–4 point screen improvements; the single study in cognitively intact older adults found only short-lived working-capacity change (Lysenko et al., 2020).

  • Baseline injury biomarkers: Neuron-specific enolase (an enzyme released by damaged neurons), antibodies to the NR2 glutamate receptor and vascular endothelial growth factor A all fell during treatment in the 801-patient program, so elevated markers may predict more gain (Mashin et al., 2023).

  • Genetic polymorphisms: No pharmacogenetic data exist. Because clearance runs through ubiquitous peptidases, variants in the liver drug-metabolizing enzymes CYP2C9 or CYP2D6 are mechanistically unlikely to alter response to this preparation.

  • Sex: Trials enrolled 58–78% women without sex-stratified analysis, so no sex difference in benefit has been established or excluded; the imbalance means male response estimates rest on smaller subgroups.

  • Pre-existing conditions: Benefit is documented where a neurological substrate exists — stroke, chronic reduced brain blood flow, diabetic nerve damage, alcohol-related brain injury, post-viral illness. Absence of such a substrate is the strongest predictor of no measurable effect.

  • Age: Adult trial populations cluster at 54–65 years and benefit signals hold into the late seventies, where baseline impairment is greater. The largest effects in the whole literature come from children aged 3–7, an age band outside this review’s audience.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the recorded harms are single-trial adverse-event tallies, spontaneous post-marketing reports and theoretical tissue-source concerns, not clinical events documented across more than one controlled trial.

Medium 🟥 🟥

Hypersensitivity Reactions, Including Anaphylaxis

Cortexin is an injected protein preparation from animal brain, so immune reaction is the mechanistically expected harm. Approved labeling lists anaphylactic shock (sudden whole-body allergic collapse), angioedema (rapid deep-tissue swelling), urticaria (hives), rash, itching and allergic dermatitis in the “very rare” frequency class. The independent systematic review of this drug class found no excess of serious adverse events against control, but its trials were small, short and underpowered for rare events (Alsulaimani & Quinn, 2021).

Magnitude: Each listed hypersensitivity reaction is labeled at a frequency below 1 in 10,000 courses; no trial has been large enough to produce an independent incidence estimate.

Injection-Site Reactions and Treatment Burden

A course means 10–20 deep intramuscular injections over 10–20 days, usually gluteal, and stroke protocols run twice daily. Labeling lists injection-site redness, fever and chills. Regional practice often reconstitutes the vial in 0.5% procaine (a local anesthetic), which adds a second sensitizing agent purely for injection comfort. In the 490-patient trial, 60 of 246 and 41 of 244 patients recorded at least one adverse event of any kind across two courses (Fedin et al., 2025).

Magnitude: 17–24% of patients per arm recorded at least one adverse event across two 10-day courses; the published tallies do not separate the injection-site fraction from other events.

Low 🟥

Neuropsychiatric and Autonomic Reactions

Labeling records psychomotor agitation (restless, purposeless movement), impaired coordination, headache, dizziness, drowsiness, reduced skin sensation, insomnia, anxiety, rapid or irregular heartbeat and raised blood pressure, each below 1 in 10,000. A 98-patient add-on trial using a structured side-effect scale recorded fewer complaints with Cortexin (Schastnyy, 2026).

Magnitude: Each reaction is labeled below 1 in 10,000 courses; no controlled trial has separated these symptoms from background rates in the treated populations.

Seizure Aggravation in Epilepsy ⚠️ Conflicted

Among 86 children and adolescents given Cortexin alongside antiepileptic drugs, seizures were not aggravated in 95% of cases, implying worsening in roughly 5% (Kalmykova et al., 2021). A 64-adult series reported the opposite, fewer seizures (Belskaya & Ponomareva, 2014). Net reading: uncontrolled data both ways.

Magnitude: About 5% of 86 treated patients showed seizure aggravation over the treatment period; the uncontrolled design provides no comparison rate against expected fluctuation.

Speculative 🟨

Transmissible Spongiform Encephalopathy Risk

The starting material is cattle brain tissue, which carries the highest theoretical load of prions (the agents of transmissible spongiform encephalopathy, a fatal brain-wasting infection). None has been reported in four decades.

Immunogenicity and Batch-to-Batch Variability

An undefined mixture of animal peptides could in principle raise anti-peptide antibodies or vary between production lots. No published assay has measured either for this product; the concern rests on composition rather than observation.

Where the vial is reconstituted in 0.5% procaine rather than saline or water, procaine hypersensitivity and local anesthetic toxicity become possible. No case series has quantified this for Cortexin; the basis is mechanistic only.

Risk-Modifying Factors

  • Allergic history: A history of reaction to any injected animal-derived protein, or of asthma, hay fever or eczema, raises the probability of the one harm the manufacturer treats as serious. It is the strongest single risk modifier.

  • Baseline eosinophils and immunoglobulin E: An elevated eosinophil count or total immunoglobulin E before starting marks an allergic phenotype, which is why protocols reserve the first administration for a supervised setting.

  • Genetic polymorphisms: No pharmacogenetic data exist for this preparation. Human leukocyte antigen variants that predispose to drug hypersensitivity are a plausible modifier of the allergic risk, but no association has been tested.

  • Sex: No sex-specific adverse-event signal has been reported. Trials were 46–78% female without sex-stratified safety analysis, so a difference has been neither established nor excluded.

  • Pre-existing conditions: Uncontrolled hypertension amplifies the labeled rare blood-pressure rise; active epilepsy carries the seizure-aggravation signal; pregnancy is an outright contraindication for lack of data rather than evidence of harm.

  • Age: Pediatric dosing is weight-based below 20 kg. At the older end of the target range, polypharmacy and reduced injection-site muscle mass matter more than any age-specific toxicity, none of which has been reported.

Key Interactions & Contraindications

  • Antiepileptic drugs (valproate, carbamazepine, levetiracetam): Caution. Used together in the pediatric epilepsy data, with seizure worsening in about 5% of an uncontrolled series (Kalmykova et al., 2021). Seizure diaries are monitored and electroencephalography considered if frequency rises.

  • Antidepressants (sertraline, escitalopram, venlafaxine): Monitor. The 98-patient add-on trial found additive symptom improvement and fewer side-effect complaints, not a pharmacokinetic interaction (Schastnyy, 2026). No dose change is required; mood is assessed at day 14 and day 28.

  • Antihypertensives (amlodipine, lisinopril, bisoprolol): Monitor. Raised blood pressure is a labeled rare reaction, so a course can transiently offset control. Blood pressure is checked at day 5 and day 10 of each course.

  • Local anesthetics used as diluent (procaine): Caution. Reconstituting in 0.5% procaine introduces anesthetic hypersensitivity risk; its para-aminobenzoic acid metabolite also antagonizes sulfonamide antibiotics. Saline or water for injection avoids both.

  • Over-the-counter sedating antihistamines (diphenhydramine, chlorphenamine): Caution. Drowsiness and impaired coordination appear on both labels, so the combination can compound daytime sedation. Morning dosing separates the two exposures.

  • Over-the-counter decongestants (pseudoephedrine, phenylephrine): Caution. Both these agents and Cortexin’s rare reaction profile can raise blood pressure and provoke palpitations. Concurrent use during a course is avoided in treated hypertension.

  • Stimulant supplements (caffeine, Rhodiola rosea, Panax ginseng): Caution. Insomnia, anxiety and rapid heartbeat are labeled rare reactions of Cortexin and expected effects of these supplements; combining them makes attribution of any new symptom impossible.

  • Other injected neuropeptide preparations (Cerebrolysin, Cellex, Semax): Caution. None has been tested in combination. A head-to-head trial found Cellex superior on neurological and cognitive recovery, so stacking adds risk without documented gain (Khabirov et al., 2020).

  • Additive supplement effects: Monitor. Supplements with their own claimed cognitive or neuroprotective action — citicoline, Ginkgo biloba, acetyl-L-carnitine — plausibly overlap in effect. No interaction study exists; the practical consequence is confounded self-assessment rather than toxicity.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel): Caution. No pharmacological interaction is known, but repeated deep intramuscular injection under anticoagulation risks muscle hematoma. The intravenous form is preferred where available.

Populations who should avoid Cortexin:

  • Pregnancy, any trimester — contraindicated in labeling for absence of clinical data
  • Breastfeeding — labeling directs stopping breastfeeding if treatment is required
  • Known hypersensitivity to Cortexin, to its glycine stabilizer, or prior anaphylaxis to any injected animal-derived protein
  • Known procaine or ester-type local anesthetic hypersensitivity, where procaine is used as the diluent
  • Uncontrolled hypertension (persistently ≥180/110 mmHg) until blood pressure is controlled
  • Therapeutic anticoagulation with an international normalized ratio above 3.0, for the intramuscular route

Risk Mitigation Strategies

  • Supervised first injection: Protocols give the first dose of a course where adrenaline is available, with 30 minutes of observation, addressing anaphylaxis — the one labeled reaction that can be fatal.

  • Saline or water as diluent: Reconstituting the 10 mg vial in 1–2 mL of 0.9% sodium chloride or water for injection rather than 0.5% procaine removes the second sensitizing agent and the sulfonamide antagonism.

  • Morning dosing: Injection before 10:00 keeps insomnia, anxiety and psychomotor agitation — the labeled reactions most often noticed — outside the sleep window.

  • Blood pressure checks during a course: Measurement at baseline, day 5 and day 10 catches the labeled rare blood-pressure rise before a full 10-day course is completed in someone already hypertensive.

  • Injection-site rotation: Alternating gluteal quadrants across the 10–20 injections of a course limits the injection-site redness, hardening and pain that dominate the recorded adverse-event tallies.

  • Course-limited exposure: Published regimens keep to 10-day courses separated by at least 10 days, two to four times a year; cumulative exposure to an animal-derived protein drives both the immunogenicity and prion concerns.

  • Seizure diary around each course: In epilepsy, logging seizure frequency for 10 days before, throughout, and 30 days after a course detects the roughly 5% aggravation signal early enough to stop.

Therapeutic Protocol

  • Standard adult course: 10 mg intramuscularly once daily for 10 consecutive days, reconstituted in 1–2 mL of saline or water for injection. This is the licensed regimen and the one used in the chronic cerebrovascular trials.

  • High-dose regimen: 20 mg daily for 10 days, popularized by Fedin’s group at Pirogov Russian National Research Medical University. Their 189-patient trial found symptom and sleep benefit dose-dependent, while the antioxidant effect was dose-independent (Fedin et al., 2018).

  • Split-dose stroke regimen: 10 mg twice daily for 10 days, repeated after a 10-day gap — the licensed acute-stroke schedule. Stakhovskaya and Shamalov’s 272-patient placebo-controlled trial used 10 mg three times daily (Aliferova et al., 2014).

  • Intravenous alternative: 10 mg intravenously has been shown therapeutically equivalent to the intramuscular route in a 490-patient trial, with comparable safety. It suits anticoagulated patients and inpatient settings (Fedin et al., 2025).

  • Competing approaches: Regional practice treats Cortexin as one of several interchangeable neuroprotective injections; a direct comparison found Cellex superior on neurological and cognitive recovery (Khabirov et al., 2020). Outside the region, standard care uses rehabilitation intensity and vascular risk control.

  • Best time of day: Morning. Sleep and asthenia outcomes improved on morning dosing in the trials, and the add-on depression trial specified a morning injection (Schastnyy, 2026); insomnia and agitation sit on the rare-reaction list.

  • Half-life: No elimination half-life has been published. As a peptide mixture it is degraded by peptidases within minutes to hours, and brain concentration tracks blood level, so effects are attributed to downstream signaling rather than drug persistence.

  • Single versus split dosing: Split dosing (10 mg twice daily) is used in acute stroke, doubling daily exposure; a single 10 mg or 20 mg morning dose is standard elsewhere. No trial has compared the schedules at matched dose.

  • Genetic polymorphisms: No pharmacogenetic dose adjustment exists. Peptidase-mediated clearance means variants in CYP2C19 (a liver drug-metabolizing enzyme) or MTHFR (which governs folate processing) have no expected effect here.

  • Sex-based differences: No sex-specific dosing has been established. Trials were predominantly female without sex-stratified dose-response analysis, so the same milligram dose is used regardless of sex or body weight in adults.

  • Age considerations: Adults receive the same dose across the range studied, including patients into their late seventies. Below 20 kg body weight, pediatric dosing is 0.5 mg/kg daily; above 20 kg, the adult 10 mg dose applies.

  • Baseline biomarkers: A baseline cognitive screen score determines whether change is measurable at all; a screen already at ceiling leaves nothing to detect. Baseline blood pressure and allergic markers determine whether a course is safe to start.

  • Pre-existing conditions: Diabetes, epilepsy, alcohol-related brain injury and post-stroke states each have their own published regimen, all built on the same 10-day, 10 mg backbone with the comparison therapy left unchanged during the course.

Discontinuation & Cycling

  • Course-based, not lifelong: The preparation is given as discrete 10-day courses, never continuously. No trial has run it beyond 20 consecutive days, and no maintenance regimen exists in any approved labeling.

  • No withdrawal syndrome: No withdrawal effects have been reported in the trial literature or in labeling. Peptidase clearance within hours and the absence of receptor downregulation data make dependence mechanistically implausible.

  • No taper required: Courses stop abruptly at day 10 in every published protocol, including the 490-patient trial (Fedin et al., 2025). No tapering schedule has been described, and no discontinuation-related adverse event has been recorded.

  • Cycling is built into the design: The trials showing the largest effects use two courses separated by 10 days, or repeat courses at six months. Benefit accrual across repeated courses, not continuous exposure, is the intended pattern.

  • Effect duration between cycles: In older adults without neurological disease, gains peaked at course end and faded over roughly two months, which sets the practical ceiling on how far apart repeat courses can be spaced (Lysenko et al., 2020).

Sourcing and Quality

  • Single originator: Cortexin is manufactured by Geropharm and its Pharm-Holding production arm in St Petersburg. Every published trial used that product, so evidence transfer to any other bovine cortical extract is unwarranted.

  • Prescription-only status: It is a prescription medicine wherever registered — Russia, Belarus, Kazakhstan, Azerbaijan, Kyrgyzstan — and is unregistered elsewhere. Retail supply outside those markets runs through export pharmacies and grey-market resellers.

  • Third-party testing does not exist: No independent laboratory verifies identity, peptide profile or sterility for this product. The certification programs that cover supplements do not extend to unregistered prescription injectables, so batch quality rests entirely on the manufacturer.

  • Counterfeit exposure: Grey-market vials are a documented counterfeit target. Verifiable batch numbers, intact holographic packaging, Cyrillic labeling matching the manufacturer’s current design and a traceable pharmacy of origin are the only practical checks available.

  • Cold chain and reconstitution: The freeze-dried cake is stored at 2–20 °C protected from light and used immediately after reconstitution. Unrefrigerated export shipping is the common failure point, and a discolored or poorly dissolving cake indicates lost integrity.

  • Formulation choice: Two strengths exist, 10 mg and a 5 mg pediatric presentation, plus an intravenous form and an investigational rectal suppository. Adults have no reason to use the 5 mg strength except to split a dose.

Practical Considerations

  • Time to effect: Changes appear during the 10-day course rather than after it, with the largest gains at course end. In the one study of people without neurological disease, gains peaked at completion and faded over about two months (Lysenko et al., 2020).

  • Common pitfall — expecting an effect without a substrate: Documented benefit comes almost entirely from stroke, reduced brain blood flow, nerve damage or post-viral symptoms. Trials in healthy adults found only short-lived work-capacity gains (Lysenko et al., 2020), not the cognitive enhancement marketed online.

  • Common pitfall — name confusion: “Cortexin” also names an unrelated endogenous neuron membrane protein and a renal peptide studied in hypertension. Search results mixing these with the drug are a recurring source of misattributed mechanism claims.

  • Common pitfall — injection technique: The product requires deep intramuscular delivery of a reconstituted powder. Shallow subcutaneous placement causes the hardening and prolonged site pain that account for much of the recorded local reaction burden.

  • Regulatory status: Cortexin holds no marketing authorization from the United States Food and Drug Administration or the European Medicines Agency, has never been assessed by either, and any use outside its registration territories is unapproved.

  • Payer incentives shape the comparison: Cortexin is among the cheapest injectable neuroprotectants in its home market, far below Cerebrolysin and Cellex, giving regional health systems a financial reason to favor it; Western systems reimburse none of the class and fund no trials of it.

  • Cost and accessibility: A 10-vial course costs roughly 1,500–2,500 rubles domestically but typically 60–150 US dollars through export vendors, plus cold-chain shipping. Cost is not the barrier; legal import and verified provenance are.

Interaction with Foundational Habits

  • Sleep: Direct and bidirectional. Sleep-questionnaire scores improved dose-dependently in the 189-patient trial (Fedin et al., 2018), plausibly via the preparation’s inhibitory receptor binding, yet insomnia sits on the rare-reaction list. Practical consequence: morning injection, and new-onset insomnia during a course is a reason to drop from 20 mg to 10 mg rather than persist.

  • Nutrition: Indirect and minor. The injected route bypasses digestion entirely, so no food timing or fasting state affects absorption. The preparation supplies free amino acids and trace elements in microgram quantities, far below dietary intake, so it cannot substitute for adequate protein or micronutrient status.

  • Exercise: Potentiating in the one study that tested a combination. Adding structured breathing exercises to a two-week course produced larger gains in working capacity than the injection alone and extended the effect to about two months, suggesting that training load rather than drug dose sets the ceiling (Lysenko et al., 2020).

  • Stress management: Direct but modest, and dose-dependent. Anxiolytic effects were significant in a diabetes trial (DIACORT, 2026) and in post-viral illness at 20 mg (Putilina et al., 2022), but insignificant after a single course in cerebrovascular disease. Practical consequence: courses sit alongside an existing stress practice rather than carrying the anxiety reduction alone.

Monitoring Protocol & Defining Success

Because Cortexin is given as a defined 10-day course rather than continuously, monitoring is built around before-and-after comparison rather than long-term surveillance. Before a first course, practitioners record a validated cognitive score, blood pressure, a complete blood count and metabolic panel, and — where any allergic history exists — eosinophil count and total immunoglobulin E, since hypersensitivity is the main labeled harm. Fasting glucose and glycated hemoglobin are added when nerve or cognitive symptoms accompany diabetes. Ongoing testing follows the course structure: the cognitive score and blood pressure are repeated at day 10, again at 4–6 weeks when reported gains peak, and before each repeat course at 3–6 month intervals. Blood count and metabolic panels are repeated annually, or immediately if a reaction occurs.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Montreal Cognitive Assessment 26–30 of 30 Primary efficacy endpoint Alternate test versions between timepoints to limit practice effects; a change of 2 or more points is the usual threshold for a real shift
Mini-Mental State Examination 28–30 of 30 Comparator to the trial data Used in most Cortexin trials, so it allows direct comparison; conventional cut-off for normal is 24 of 30, well below the functional target; less sensitive than the Montreal test at high baseline scores
Blood pressure 110–125 / 70–80 mmHg Detects the labeled rare pressure rise Seated, after 5 minutes rest, same arm each time; conventional cut-off is 140/90 mmHg, well above the functional target
Eosinophil count 0.0–0.15 ×10⁹/L Marks allergic phenotype before first exposure Part of a complete blood count; conventional upper limit is 0.5 ×10⁹/L; best paired with total immunoglobulin E
Total immunoglobulin E Below 60 IU/mL Quantifies baseline allergic risk Conventional cut-off is 100 IU/mL; no fasting needed; warranted only where an allergic history exists
Glycated hemoglobin 4.8–5.4% Tracks the metabolic signal seen in the diabetes trial Conventional target is below 5.7%; no fasting needed; reflects the preceding 8–12 weeks
High-sensitivity C-reactive protein Below 1.0 mg/L Background inflammatory load that modifies cognitive trajectory Conventional cut-off is 3.0 mg/L; invalid within 2 weeks of infection or injury; fasting not required
Homocysteine Below 8 µmol/L Modifiable vascular contributor to cognitive decline Conventional cut-off is 15 µmol/L; fasting sample, with plasma separated within 1 hour
Neuron-specific enolase No established functional target — track change from the individual’s own baseline Marker of neuronal stress that fell during Cortexin therapy (Mashin et al., 2023) Research use only; hemolyzed samples are invalid; best paired with the cognitive score at the same visit
Multidimensional Fatigue Inventory No established target — track change from the individual’s own baseline Quantifies the asthenia endpoint the drug is most used for Twenty-item self-report; completed at the same time of day each visit; reference norms are population-specific

Qualitative markers carry as much weight here as the laboratory panel, since the endpoints that moved in the trials were symptom scales rather than biochemistry:

  • Sleep quality and time to fall asleep, tracked nightly through each course
  • Daytime energy and endurance for cognitively demanding work
  • Word-finding, name recall and reading comprehension
  • Mood, irritability and anxiety, especially after day 14
  • Injection-site comfort, and any rash, itch or flushing within 30 minutes of a dose

Emerging Research

  • No registered trials on ClinicalTrials.gov: A direct search of ClinicalTrials.gov on 31 August 2026 returned no Cortexin studies. Every trial below is registered instead in the Russian state medicines registry and reported only on publication, which limits protocol pre-specification checks.

  • Diabetic complications trial reported: The 110-patient DIACORT randomized multicenter trial in neurological complications of type 2 diabetes reported nerve-symptom, cognitive, mood and glycated hemoglobin benefits, with five adverse events across both arms (DIACORT, 2026).

  • Route-equivalence program: A 490-patient randomized double-blind trial established the intravenous form as no less effective than intramuscular in acute stroke, opening the way to infusion protocols and to use in anticoagulated patients (Fedin et al., 2025).

  • Psychiatric add-on line: A 98-patient trial of Cortexin added to antidepressants reported greater symptom reduction and fewer side-effect complaints than antidepressants alone, extending the research program from neurology into psychiatry (Schastnyy, 2026).

  • Non-injectable formulation: Rectal suppository delivery achieved brain distribution comparable to intramuscular injection in radiolabeled rodent work, the first credible route that would remove the injection burden if it reaches human trials (Kurkin et al., 2025).

  • New mechanistic target: Work on brain injury caused by blood flow returning to starved tissue reports modulation of the osteoprotegerin-RANK-RANKL axis (a bone-remodeling signaling pathway also active in injured brain) and of the TRPC1 calcium channel (Guven et al., 2026).

  • Evidence that could weaken the case: A randomized head-to-head trial found Cellex superior to Cortexin on neurological and cognitive recovery after stroke, and the sole independent systematic review rated the certainty of all animal-derived nootropic evidence low to very low (Khabirov et al., 2020; Alsulaimani & Quinn, 2021).

  • The decisive open question: No trial has been run outside the manufacturer’s home region, and none has enrolled cognitively intact adults with an aging endpoint. Either would change how much weight the existing body of work can bear.

Conclusion

Cortexin is an injected extract of cattle brain cortex, given as short courses of daily injections rather than as a daily tablet. The strongest evidence sits where it has been used longest: recovery of movement and independence after a stroke caused by a blocked artery, and improvement on standard thinking tests in people with long-standing reduced brain blood flow. Those gains are consistent but small. Single trials also point to less fatigue, better sleep, calmer mood and relief of nerve symptoms in diabetes.

For an adult without neurological disease the picture is thinner. The few studies in that group found gains in working capacity that faded within about two months, and nothing has tested the preparation against any measure of aging itself.

Recorded harms are few and mostly mild, dominated by allergic reactions and the burden of ten to twenty injections per course. Because the raw material is animal nervous tissue, a theoretical infection concern remains, unobserved across nearly four decades of use.

The real weakness lies in the evidence base rather than the findings. Almost all human research comes from one region, much of it from the manufacturer or from researchers it funds, often without a dummy-injection comparison group, and the single independent appraisal judged the certainty very low. Confidence here is limited far more by who produced the evidence, and how, than by what the evidence reports.

Top - Benefits - Risks - Protocol